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factors (P<.05). Using multivariate analysis, left ventricular hypertrophy
(LVH) was the strongest risk factor of HF (OR= 25.4, 95%CI=21-31), fol-
lowed by the presence of heart valve disease (OR=4.1, 95%CI=2.7-6.3), par-
oxystic or permanent atrial fibrillation (OR=4.05, 95%CI=3.1-5.3), renal
dysfunction, history of myocardial infarction and coronary artery disease
(OR<3 for each of them).
 
Conclusion:
 
 As suspected, LVH is the strongest risk factor for HF in
hypertension, while a majority of pts presented with > 3 risk factors for HF.
This study highlights the need for an early management of HF risk factors in
hypertensive pts. 
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We evaluated left ventricular remodeling (LVR) in patients (pts) with
heart failure (HF) of the 2 main aetiologies, coronary artery disease (CAD)
and dilated cardiomyopathy (DCM) after 1 year (y) of cardiac resynchroniza-
tion therapy (CRT). We enrolled 65 HF outpts with CRT indication (mean
age 67.5±13.2 ys 74.6% males, M): 33 had CAD-caused HF (70.2±6.7 ys,
84.4% M) and 32 DCM (64.6±17.3 ys, 64.5% M). All underwent ECG,
echocardiography, NYHA evaluation before and after 1 y of CRT. Before
CRT, NYHA was similar (CAD 2.7±0.7, DCM 2.7±0.8) and after 1 y it sig-
nificantly (p<0.05) and equally improved in both (CAD 2.3±0.5, DCM
2.2±0.7). Before CRT left ventricular ejection function (EF,%) was signifi-
cantly (p=0.04) less in DCM (22.9±7.7) than CAD (26.3±7.3) while end-dias-
tolic (EDV, ml) and end-systolic (ESV) volume, end-diastolic (EDD, mm)
and end-systolic (ESD) diameter were significantly greater in DCM than
CAD (EDV 239±78 vs 207±62 p=0.04, ESV 192±81 vs 152±57 p=0.03,
EDD 72.8±8.1 vs 68.8±8.6 p=0.05, ESD 59.5±10.7 vs 53.8±8.8 p=0.03).
After 1 y EF significantly improved in both (DCM 28.8±9.5 p=0.01, CAD
29.5±7.4 p=0.05) with a borderline trend to a greater increase in DCM. After
1 y EDV, ESV, EDD and ESD were reduced in both, with a significant reduc-
tion only in DCM. Expressing LVR as the volume parameters variation (
 
Δ
 
),
it was significantly greater in DCM than CAD: 
 
Δ
 
EDV DCM 44±72 vs CAD
20±34, p=0.04; 
 
Δ
 
ESV DCM 47±64 vs CAD 19±35, p=0.04. Before CRT
QRS duration (msec) was similar in both (DCM 172±33 CAD 176±28, p=ns)
as well as after (DCM 123±33 CAD 134±31, p=ns). Pre and post-CRT QRS
duration and 
 
Δ
 
QRS weren’t related to any modification of the above indi-
cated parameters, both in the overall population and the 2 groups. Thus, CRT
determines EF increase and LVR regression in both examined HF aetiologies.
Volume reduction is greater in DCM than CAD. No relation exists between
the volume and function parameters modifications and QRS duration both
before and after CRT. 
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Purpose:
 
 It remains unknown whether heart rate reduction by the I
 
f
 
 current
inhibitor ivabradine (IVA) improves left ventricular (LV) function of the inf-
arcted and reperfused myocardium. Accordingly, our goal was to investigate
the effect of IVA on global and regional LV function following myocardial
infarction and long term reperfusion in rabbits.
 
Methods:
 
 Myocardial systolic function was assessed before a 20 min cor-
onary artery occlusion and during the subsequent 3 weeks of reperfusion by
echocardiography and tissue tracking imaging. Throughout reperfusion, rabbits
received either IVA (10 mg/kg/day, n=9) or vehicle (Control, n=8) using
implanted osmotic pumps. At 3 weeks reperfusion, LV remodeling was inves-
tigated by histology and expression of several proteins (SERCA2a, RyR2-P,
phospholamban, FKBP12) involved in calcium handling.
 
Results:
 
 After 3 weeks, IVA induced a significant decrease in heart rate by
 
≈
 
20% as compared to Control (214±9 
 
vs
 
 266±14 bpm, respectively). In Con-
trol rabbits, ejection fraction and regional systolic displacement were signifi-
cantly decreased as compared to baseline values (43±4% vs 63±2% and
1.4±0.2 vs 2.8±0.2 mm, respectively) and were associated with LV enlarge-
ment and interstitial fibrosis within the reperfused zone (risk zone: 30±2% of
LV and infarct size: 8% of LV). Chronic administration of IVA prevented the
reduction in ejection fraction (58±3% vs 66±3% in baseline) and the decrease
in regional systolic displacement (1.9±0.3 vs 2.6±0.3 mm). This improvement
was not related to a difference in infarct size and interstitial fibrosis. Interest-
ingly, this was associated with a significant increase in FKBP12 expression in
the reperfused area without any changes in SERCA2a, RyR2-P and phospho-
lamban.
 
Conclusion:
 
 
 
Heart rate reduction with IVA significantly improves systolic
function after 3 weeks of reperfusion. This beneficial effect might result from
an adaptation of calcium handling as suggested by the increase in FKBP12
expression.
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The aim
 
 of the present work was to investigate changes in heart architec-
ture after chemical sympathetic denervation by 6OH-Dopamine (6OH-DA) in
mice.
Two months old mice (n=18) received 3 6OH-DA injections (200 mg/kg,
ip) or saline (n = 6) at 3 days of interval. 15 and 30 days after first injec-
tion, heart rate spectral variability (HRV, FFT) was analyzed in low frequency
(LF: 0.15-1.5 Hz) and high frequency (HF: 1.5-5 Hz) ranges and LH/HF ratio
was calculated. After sacrifice, blood was withdrawn for catecholamine deter-
mination (HPLC). Hearts were fixed (formaldehyde 10%) for histology or
frozen for western blot analysis (tyrosine hydroxylase, TH).
 
Results
 
 indicate that compared to controls (1410±145 pg/ml) plasma nore-
pinephrine levels were significantly lower at D15 (766±186 pg/ml) and D30
(675±288 pg/ml) after 6OH-DA without change in epinephrine. TH expression
was absent at D15 and significantly lower than in controls at D30. When com-
Group 1 Group 2p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
p<0.01
100
90
80
70
60
50
40
30
20
10
0
LVG Valvulopathy Atrial fibrillation Renal Failure Myocardial infarct Coronaropathy
 
January 15
 
th
 
, Friday 2010
